Pci Biotech Holding Asa · LSE:0JGL
Pci Biotech Holding Asa — FY2023 Earnings Presentation
16 slides from Pci Biotech Holding Asa's earnings presentation, Feb 14, 2024
Slide 1: Preliminary full year 2023 Interim Report
PCI Biotech - Preliminary full year 2023 Interim Report Presentation February 14, 2024 Ronny Skuggedal, CEO / CFO Morten Luhr, BD Manager www.pcibiotech.com
Slide 2: Important notice and disclaimer
PCI Biotech Important notice and disclaimer This presentation may contain certain forward-looking Factors that could cause these differences include, but are not limited to, statements and forecasts based on uncertainty, since they implementation of PCI Biotech’s strategy and its ability to further
Slide 3: Table of Contents
Table of Contents Operational review - highlights Key financials Outlook Q&A www.pcibiotech.com 3
Slide 4: Gene therapy - advanced medicinal products with groundbreaking potential
Highlights GENE THERAPY – ADVANCED MEDICINAL PRODUCTS WITH GROUNDBREAKING POTENTIAL 2H 2023 IN VIVO GENE THERAPY EX VIVO GENE THERAPY Genetic disorders are caused by DNA mutations fimaNAC that may lead to severe disease Bioprocessing Gene therapies are potentially life-saving treatments for gene
Slide 5: Viral vector manufacturing - utilising cells as gene therapy factories
Highlights VIRAL VECTOR MANUFACTURING - UTILISING CELLS AS “GENE THERAPY FACTORIES” 2H 2023 fimaNAC Bioprocessing Upstream yield Net yield Manufacturing challenges for viral vectors include host-cell impurities (e.g. DNA and protein) and low viral vector yield from cell lysis www.pcibiotech.com 5
Slide 6: Photochemical lysis (PCL) - next generation viral vector extraction
Highlights PHOTOCHEMICAL LYSIS (PCL) - NEXT GENERATION VIRAL VECTOR EXTRACTION 2H 2023 fimaNAC Bioprocessing PCI Biotech develops a novel technology - photochemical lysis (PCL) - to address technical needs in viral vector manufacturing Photochemical lysis selectively releases viral vectors from prod
Slide 7: Photochemical lysis vs industry standard viral vector extraction
Highlights PHOTOCHEMICAL LYSIS (PCL) - NEXT GENERATION VIRAL VECTOR EXTRACTION 2H 2023 fimaNAC Bioprocessing Viral vector extraction Mode of action Net viral vector yield Host-cell impurities Industry standard Non-selective Moderate High Photochemical lysis potential Selective High Low www.pcibiotec
Slide 8: Important R&D milestones
Highlights IMPORTANT R&D MILESTONES 2H 2023 • Photochemical lysis has demonstrated viral vector release across several adeno-associated virus (AAV) serotypes in an upstream process fimaNAC Bioprocessing • Broad international patent application has been filed with encouraging search report • Photoche
Slide 9: Early-stage field (alpha) testing with undisclosed partner
Highlights EARLY-STAGE FIELD (“ALPHA”) TESTING WITH UNDISCLOSED PARTNER 2H 2023 fimaNAC Test setup - upstream process Bioprocessing Photochemical lysis was tested in partner’s PCI Biotech ultra scale-down AAV model upstream AAV process development process with suspension HEK293 cells in shake flasks
Slide 10: The path from feasibility tests to commercial manufacturing
Highlights THE PATH FROM FEASIBILITY TESTS TO COMMERCIAL MANUFACTURING 2H 2023 Feasibility Prototype Commercial fimaNAC Bioprocessing Plate Shake-flask Mini benchtop bioreactor Benchtop bioreactor Bioreactor (0.5-1 mL) (20 mL) (250 mL) (1-10 L) (50-500 L) 2022 2023 2024 Partner-dependent Partner-dep
Slide 11: The viral vector manufacturing market
Highlights THE VIRAL VECTOR MANUFACTURING MARKET 2H 2023 AAV gene therapy Target indication FDA approval List price (per treatment) fimaNAC 1 Hemgenix Hemophilia B 2022 $ 3.5 million Bioprocessing Zolgensma Spinal muscular 2019 $ 2.1 million atrophy Luxturna Retinal dystrophy 2017 $ 825 000 (both ey
Slide 12: Corporate highlights: financial runway and 2024 focus areas
Highlights 2H 2023 Corporate Estimated financial runway Cash position of NOK 41 million supports operations into 2025, with current plans Opportunity window to demonstrate commercial potential of the platform Continue to explore financing and strategic opportunities 2024 focus areas Cont
Slide 13: Key financials, Outlook, Q&A
Key financials Outlook Q&A 13
Slide 14: Finance: key financial figures
Finance 2H 2023 Key financial figures Cash position estimated to support operations into 2025 Year-end cash position at NOK 41 million Net change in cash of NOK -15 million during 2023 Public grants reduced based on R&D cost reductions The 2022 restructuring makes comparison of figures not
Slide 15: Outlook
Outlook Leveraging the technology platform within bioprocessing, dermatology, and immunotherapy 2023 Achievements 2024 Goals - Bioprocessing Milestones Bioprocessing IP broadened for all programmes • Complete early-stage field testing Data from ultra scale-down model attracted industry interest • De
Slide 16: PCI Biotech enquiries
PCI Biotech PCI Biotech For enquiries: Ronny Skuggedal, CEO / CFO Mobile phone: +47 940 05 757 E-mail: rs@pcibiotech.com www.pcibiotech.com 16